TRVI TREVI THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TREVI THERAPEUTICS INC reported revenue of n/a, net income of −$17.8M and diluted EPS of −$0.11; for the fiscal year ended December 2025 revenue was n/a.
TRVI annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$49.3M, net income −$42.8M (margin n/a), EPS −$0.32
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$51.5M, net income −$47.9M (margin n/a), EPS −$0.47
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$33.9M, net income −$29.1M (margin n/a), EPS −$0.29
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$29.9M, net income −$29.2M (margin n/a), EPS −$0.45
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$32.5M, net income −$33.9M (margin n/a), EPS −$1.49
TRVI quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$17.8M, EPS −$0.11
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.2M, EPS −$0.09
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$8.32M, EPS −$0.06
- Quarter ended Sep 30, 2025: revenue n/a, net income −$11.8M, EPS −$0.08
- Quarter ended Jun 30, 2025: revenue n/a, net income −$12.3M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income −$10.3M, EPS −$0.09
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$11.4M, EPS −$0.11
- Quarter ended Sep 30, 2024: revenue n/a, net income −$13.2M, EPS −$0.13
- Quarter ended Jun 30, 2024: revenue n/a, net income −$12.4M, EPS −$0.12
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.9M, EPS −$0.11
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.83M, EPS −$0.08
- Quarter ended Sep 30, 2023: revenue n/a, net income −$7.70M, EPS −$0.08
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.15M, EPS −$0.07
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.40M, EPS −$0.06
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.51M, EPS $0.05
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.27M, EPS −$0.12
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.05M, EPS −$0.14
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.33M, EPS −$0.24
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$8.52M, EPS −$0.23
- Quarter ended Sep 30, 2021: revenue n/a, net income −$7.26M, EPS −$0.34
TRVI cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$42.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$38.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$31.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$28.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$28.9M, share buybacks n/a
TRVI balance sheet
- Jun 30, 2026: cash $54.3M, total assets $331M, total liabilities $9.01M, shareholders' equity $322M
- Mar 31, 2026: cash $19.4M, total assets $180M, total liabilities $7.48M, shareholders' equity $172M
- Dec 31, 2025: cash $18.9M, total assets $193M, total liabilities $10.2M, shareholders' equity $183M
- Sep 30, 2025: cash $56.9M, total assets $199M, total liabilities $9.57M, shareholders' equity $190M
- Jun 30, 2025: cash $117M, total assets $208M, total liabilities $9.85M, shareholders' equity $198M
- Mar 31, 2025: cash $19.4M, total assets $107M, total liabilities $7.55M, shareholders' equity $99.5M
- Dec 31, 2024: cash $34.1M, total assets $111M, total liabilities $11.3M, shareholders' equity $99.6M
- Sep 30, 2024: cash $16.1M, total assets $68.9M, total liabilities $9.94M, shareholders' equity $59.0M
Is TRVI profitable?
No. TREVI THERAPEUTICS INC lost $51.1M over the last four quarters.
What is TRVI's EPS?
Diluted earnings per share over the last four quarters were −$0.34; −$0.11 in the latest quarter.